Investment Mandate
“Our investment strategy is keenly focused on small to mid-size biotechs, in our target therapeutic areas
(neuroscience, gastroenterology, oncology and anti-aging).”
Toxicology Programs
Completed genotoxicology, safety pharmacology, and general toxicology
Chemistry, Manufacturing,
and Controls
Completed API selection, drug product formulation, and cGMP manufacturing.
Efficacy Signal Evaluation
Looking for promising results from animal efficacy models, off-label physician use, or other pharmacodynamic data.
IND opened or pre-IND
complete
“Our approach combines scientific rigor with strategic business insight, ensuring
that we invest in companies poised for significant impact in the biotech landscape.”
Our preference is to partner with phase 1 or phase 2 ready biotechs to accelerate progress and improve the probability of success